The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Bariakh E.A.
Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii
Misyurina A.E.
Hematology Research Center, Ministry of Health of Russia, Moscow, Russia
Kovrigina A.M.
Nauchno-klinicheskoe otdelenie gematologicheskoĭ khirurgii Gematologicheskogo nauchnogo tsentra Minzdrava RF, Moskva
Obukhova T.N.
FGBU "Gematologicheskiĭ nauchnyĭ tsentr" Minzdrava Rossii, Moskva
Gemdzhyan E.G.
National Research Center for Hematology, Moscow, Russia
Vorob’ev V.I.
S.P. Botkin State Clinical Hospital, Moscow, Russia
Mangasarova Ia.K.
Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii
Polyakov Yu.Yu.
Hematology Research Center, Ministry of Health of Russia, Moscow, Russia
Magomedova A.U.
Federal Research and Clinical Center of Sports Medicine, Federal Biomedical Agency of the Russia, Moscow, Russia
Kliasova G.A.
Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva
Misyurin V.A.
Hematology Research Center, Ministry of Health of Russia, Moscow, Russia
Iatsyk G.A.
Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva
Shevelev A.A.
Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva
Kostina I.É.
Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva
Vorob'ev A.I.
Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii
Kravchenko S.K.
Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii
Diagnosis and treatment in patients with B-cell lymphoma unclassified that is intermediate between diffuse large B-cell lymphoma and Burkitt’s lymphoma
Journal: Therapeutic Archive. 2015;87(8): 77‑85
Views: 1907
Downloaded: 480
To cite this article:
Bariakh EA, Misyurina AE, Kovrigina AM, et al. . Diagnosis and treatment in patients with B-cell lymphoma unclassified that is intermediate between diffuse large B-cell lymphoma and Burkitt’s lymphoma. Therapeutic Archive.
2015;87(8):77‑85. (In Russ.)
https://doi.org/10.17116/terarkh201587877-85
Aim. To characterize a group of patients with B-cell lymphoma (BCLU) unclassified that is intermediate between diffuse large B-cell lymphoma and Burkitt’s lymphoma, to identify poor prognostic factors, and to evaluate therapeutic efficiency in patients with BCLU. Subjects and methods. Twenty-five patients with BCLU were examined. Double-hit lymphoma (DHL) was diagnosed in 8 (32%) patients. According to the Ann-Arbor classification of lymphoma, its stages II, III, and IV were diagnosed in 3 (12%), 2 (8%), and 20 (80%) patients, respectively. MYC rearrangement was observed in 11 (48%) out of 23 patients: single-hit lymphoma in 3 patients and DHL in 8 (BCL2+/MYC+ in 6 cases and BCL6+/MYC+ in 2). The expression of с-MYC (cut off ≥40%) was revealed in 17 (74%) out of 23 patients; that of BCL2 (cut off ≥50%) was detected in 14 (58%) out of 24 patients; coexpression of both proteins was seen in 12 (52%) out of 23 patients. The DHL group showed a correlation between the rearrangement of the BCL2+/MYC+ genes and the expression of MYC and BCL2 proteins in 5 out of 6 patients. Taking into account the heterogeneity of the entire patient group, DHL and non-DHL subgroups were considered separately. Both subgroups were comparable by clinical characteristics. BCLU patients younger than 60 years of age received treatment according to the LB-M-04 ± rituximab; those aged 60 or older had CHOP-like regimens ± rituximab. Autologous stem cell transplantation (auto-SCT) was performed in 5 patients belonging to a high-risk group. Results. The 3-year overall survival (OS) was 62% and the 3-year event-free survival (EFS) was 51%. The 3-year OS was lower for the DHL group than that for the non-DHL group (43 and 75%, respectively). Conclusion. In the DHL group, both OS and EFS are significantly lower (the risk of poor outcome, including death, is higher) than those in the non-DHL group. It is conceivable that intensified chemotherapy with auto-SCT increases treatment results in patients with BCLU; however, a larger number of observations are needed to obtain valid data.
Keywords:
Authors:
Bariakh E.A.
Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii
Misyurina A.E.
Hematology Research Center, Ministry of Health of Russia, Moscow, Russia
Kovrigina A.M.
Nauchno-klinicheskoe otdelenie gematologicheskoĭ khirurgii Gematologicheskogo nauchnogo tsentra Minzdrava RF, Moskva
Obukhova T.N.
FGBU "Gematologicheskiĭ nauchnyĭ tsentr" Minzdrava Rossii, Moskva
Gemdzhyan E.G.
National Research Center for Hematology, Moscow, Russia
Vorob’ev V.I.
S.P. Botkin State Clinical Hospital, Moscow, Russia
Mangasarova Ia.K.
Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii
Polyakov Yu.Yu.
Hematology Research Center, Ministry of Health of Russia, Moscow, Russia
Magomedova A.U.
Federal Research and Clinical Center of Sports Medicine, Federal Biomedical Agency of the Russia, Moscow, Russia
Kliasova G.A.
Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva
Misyurin V.A.
Hematology Research Center, Ministry of Health of Russia, Moscow, Russia
Iatsyk G.A.
Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva
Shevelev A.A.
Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva
Kostina I.É.
Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva
Vorob'ev A.I.
Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii
Kravchenko S.K.
Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.